PT  - JOURNAL ARTICLE
AU  - Sosinski, Lauren M.
AU  - Martin H, Christian
AU  - Neugebauer, Kerri A.
AU  - Ghuneim, Lydia-Ann J.
AU  - Guzior, Douglas V.
AU  - Castillo-Bahena, Alicia
AU  - Mielke, Jenna
AU  - Thomas, Ryan
AU  - McClelland, Marc
AU  - Conrad, Doug
AU  - Quinn, Robert A.
TI  - Trikafta therapy alters the CF lung mucus metabolome reshaping microbiome niche space
AID  - 10.1101/2021.06.02.21257731
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.02.21257731
4099  - http://medrxiv.org/content/early/2021/06/04/2021.06.02.21257731.short
4100  - http://medrxiv.org/content/early/2021/06/04/2021.06.02.21257731.full
AB  - Background Novel small molecule therapies for cystic fibrosis (CF) are showing promising efficacy and becoming more widely available since recent FDA approval. The newest of these is a triple therapy of Elexacaftor-Tezacaftor-Ivacaftor (ETI, Trikafta®). Little is known about how these drugs will affect polymicrobial lung infections, which are the leading cause of morbidity and mortality among people with CF (pwCF).Methods we analyzed the sputum microbiome and metabolome from pwCF (n=24) before and after ETI therapy using 16S rRNA gene amplicon sequencing and untargeted metabolomics.Results The lung microbiome diversity, particularly its evenness, was increased (p = 0.044) and the microbiome profiles were different between individuals before and after therapy (PERMANOVA F=1.92, p=0.044). Despite these changes, the microbiomes were more similar within an individual than across the sampled population. There were no specific microbial taxa that were different in abundance before and after therapy, but collectively, the log-ratio of anaerobes to classic CF pathogens significantly decreased. The sputum metabolome also showed changes due to ETI. Beta-diversity increased after therapy (PERMANOVA F=4.22, p=0.022) and was characterized by greater variation across subjects while on treatment. This significant difference in the metabolome was driven by a decrease in peptides, amino acids, and metabolites from the kynurenine pathway. Metabolism of the three small molecules that make up ETI was extensive, including previously uncharacterized structural modifications.Conclusions This study shows that ETI therapy affects both the microbiome and metabolome of airway mucus. This effect was stronger on sputum biochemistry, which may reflect changing niche spaces for microbial residency in lung mucus as the drug’s effects take hold, which then leads to changing microbiology.Funding This project was funded by a National Institute of Allergy and Infectious Disease Grant R01AI145925Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to acknowledge funding from the National Institutes of Allergy and Infectious Diseases under R01 grant R01AI145925 awarded to PI Quinn.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the collections at the University of California San Diego adult CF clinic was obtained from the UCSD Human Research Protections Program Institutional Review Board under protocol #160078. Institutional review board approval was also provided for the collections at the Spectrum Health adult CF clinic in Grand Rapids, MI by the Spectrum Health Human Research Protection Program Office of the Institutional Review Board under IRB #2018-438.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe mass spectrometry data were deposited on public repository massive.ucsd.edu under MassIVE ID MSV000087364.